Ligand Pharmaceuticals Incorporated LGND

Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell’s CAR-T therapy programs. The agreement extends Ligand’s royalty-focused approach, giving the business potential future royalty rights on AvenCell’s existing CAR-T pipeline and any later programs that emerge from the partnership. Recent trading has been strong for...

Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today. With a Discounted Cash Flow (DCF) view available, the focus naturally turns to how the current price lines up with the cash flows investors expect the company to produce over time. Over the past 3 years, Ligand Pharmaceuticals has returned about 430.8%, which puts a lot of weight on whether the cash flow...

Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs. The deal deepens Ligand’s royalty-focused model by adding potential royalty streams on AvenCell’s current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. We’ll now examine...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers. Rather than relying on internally operated drug development programs, the company funds third-party programs and acquires royalty interests in exchange for economic rights in those assets. That model allows it to generate royalties and other income when the […]

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the t

DEL MAR, Calif., September 22, 2026--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA).

Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Directors.

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryj

On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]

JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.H.C. Wainwright

On the latest list of new buys by top funds, Ligand stock targets a breakout but faces this test first.

Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while traditional market multiples suggest the shares are pricing in a richer outlook. Ligand Pharmaceuticals has delivered a very large 5 year return of 337.4%, which puts extra focus on whether the current price still offers a margin of safety. The recent expansion of its royalty portfolio and...

Ligand Pharmaceuticals (LGND) is back in focus after its recent second quarter report and reaffirmed 2026 guidance. The company posted US$63.69 million in quarterly revenue and US$48.51 million in net income. See our latest analysis for Ligand Pharmaceuticals. The latest earnings report and reaffirmed 2026 guidance have come after a strong run for Ligand Pharmaceuticals, with a 90 day share price return of 33.93% and a 1 year total shareholder return of 87.99%. If this kind of multi year...

The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic cap

By John Vandermosten, CFA NASDAQ: LGND READ THE FULL LGND RESEARCH NOTE Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported second quarter 2026 results boasting total revenue and income of $63.7 million, a 34% year over year increase. Adjusted core earnings per share (EPS) of $2.37 were also impressive, rising 48%. By line item, royalties rose 32%, and contract revenue increased by 161%.